JP2023528755A5 - - Google Patents
Info
- Publication number
- JP2023528755A5 JP2023528755A5 JP2022569071A JP2022569071A JP2023528755A5 JP 2023528755 A5 JP2023528755 A5 JP 2023528755A5 JP 2022569071 A JP2022569071 A JP 2022569071A JP 2022569071 A JP2022569071 A JP 2022569071A JP 2023528755 A5 JP2023528755 A5 JP 2023528755A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- nucleic acid
- oligomer compound
- equal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038024P | 2020-06-11 | 2020-06-11 | |
| US63/038,024 | 2020-06-11 | ||
| US202063045728P | 2020-06-29 | 2020-06-29 | |
| US63/045,728 | 2020-06-29 | ||
| US202163178203P | 2021-04-22 | 2021-04-22 | |
| US63/178,203 | 2021-04-22 | ||
| PCT/US2021/036873 WO2021252799A2 (en) | 2020-06-11 | 2021-06-10 | Compounds and methods for reducing msh3 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528755A JP2023528755A (ja) | 2023-07-06 |
| JP2023528755A5 true JP2023528755A5 (cg-RX-API-DMAC7.html) | 2024-06-17 |
Family
ID=78846536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022569071A Pending JP2023528755A (ja) | 2020-06-11 | 2021-06-10 | Msh3の発現を低減するための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230235331A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4164656A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023528755A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021252799A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4146807A4 (en) * | 2020-05-08 | 2024-09-04 | Takeda Pharmaceuticals U.S.A., Inc. | METHODS OF TREATING NUCLEOTIDE AMPLIFICATION DISEASES ASSOCIATED WITH MSH3 ACTIVITY |
| WO2023168304A2 (en) * | 2022-03-02 | 2023-09-07 | Triplet Therapeutics, Inc. | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |
| JP2025516554A (ja) * | 2022-05-10 | 2025-05-30 | エフ. ホフマン-ラ ロシュ アーゲー | Cfp-elk1遺伝子間領域を標的とするアンチセンスオリゴヌクレオチド |
| WO2026050519A2 (en) * | 2024-08-28 | 2026-03-05 | Latus Bio, Inc. | Microrna knockdown of msh3 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| EP1888083B1 (en) * | 2005-05-24 | 2011-12-28 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to lmw-ptpase |
| EP3052632A4 (en) * | 2013-10-04 | 2017-03-29 | Rana Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| WO2015171918A2 (en) * | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
| US10633410B2 (en) * | 2014-12-22 | 2020-04-28 | University Of Iowa Research Foundation | Nucleic acid aptamers to treat histone-induced disease states |
| EP4279084B1 (en) * | 2015-10-28 | 2025-06-11 | Vertex Pharmaceuticals Inc. | Materials and methods for treatment of duchenne muscular dystrophy |
| WO2020117702A1 (en) * | 2018-12-03 | 2020-06-11 | Triplet Therapeutics, Inc. | Methods for the treatment of trinucleotide repeat expansion disorders associated with msh3 activity |
| WO2021216556A2 (en) * | 2020-04-20 | 2021-10-28 | University Of Massachusetts | Oligonucleotides for msh3 modulation |
| EP4146807A4 (en) * | 2020-05-08 | 2024-09-04 | Takeda Pharmaceuticals U.S.A., Inc. | METHODS OF TREATING NUCLEOTIDE AMPLIFICATION DISEASES ASSOCIATED WITH MSH3 ACTIVITY |
-
2021
- 2021-06-10 EP EP21820917.9A patent/EP4164656A4/en active Pending
- 2021-06-10 JP JP2022569071A patent/JP2023528755A/ja active Pending
- 2021-06-10 US US18/001,241 patent/US20230235331A1/en active Pending
- 2021-06-10 WO PCT/US2021/036873 patent/WO2021252799A2/en not_active Ceased